Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia

Pediatric Blood and Cancer

Volumn 47, Issue 5 SUPPL., 2006, Pages 710-713

  Crow, Andrew R ^a,b,d   Song, Seng ^b,d   Siragam, Vinayakumar ^a,b,d   Lazarus, Alan H ^a,b,c,d  

^a CANADIAN BLOOD SERVICES   (Canada)

^b Department of Laboratory Medicine ^*  (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d Toronto Platelet Immunobiology Group   (Canada)

Author keywords

Immune complex; Intravenous immunoglobulin; ITP

Indexed keywords

AUTOANTIBODY; CD11 ANTIGEN; CYTOKINE; FC RECEPTOR; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INHIBITION KINETICS; MONONUCLEAR PHAGOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MICE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, IGG;

EID: 33748500435     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20980     Document Type: Review

References (34)

1. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-1231.
2. Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet 1983;2:193-195.
3. Salama A, Kiefel V, Amberg R, et al. Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies [anti-RhO(D)]. Blut 1984;49:29-35.
4. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982;306:1254-1258.
5. Crow AR, Song S, Semple JW, et al. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol 2001;115:679-686.
6. Siragam V, Brinc D, Crow AR, et al. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest 2005;115:155-160.
7. Crow AR, Lazarus AH. Role of Fcg receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003;25:S14-S18.
8. Nimmerjahn F, Ravetch JV. Fcgamma receptors: Old friends and new family members. Immunity 2006;24:19-28.
9. Ericson SG, Coleman KD, Wardwell K, et al. Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes. Br J Haematol 1996;92:718-724.
10. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484-486.
11. Kurlander RJ, Hall J. Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest 1986;77:2010-2018.
12. Song S, Crow AR, Siragam V, et al. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood 2005;105:1546-1548.
13. Song S, Crow AR, Freedman J, et al. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: An alternative to IVIG. Blood 2003;101:3708-3713.
14. Burdach SE, Evers KG, Geursen RG. Treatment of acute idiopathic thrombocytopenic purpura of childhood with intravenous immunoglobulin G: Comparative efficacy of 7S and 5S preparations. J Pediatr 1986;109:770-775.
15. Tovo PA, Miniero R, Fiandino G, et al. Fc-depleted vs intact intravenous immunoglobulin in chronic ITP. J Pediatr 1984;105:676-677.
16. Webster ML, Sayeh E, Crow M, et al. Relative efficacy of immunoglobulin G in ameliorating thrombocytopenia induced by anti-platelet GPIIbIIIa versus GPIb alpha antibodies. Blood 2006; doi: 10.1182/blood-2005-06-009761.
17. Nieswandt B, Bergmeier W, Rackebrandt K, et al. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood 2000;96:2520-2527.
18. Crow AR, Song S, Freedman J, et al. IVIg-mediated amelioration of murine ITP via Fc{gamma}RIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 2003;102:558-560.
19. Ott VL, Fong DC, Cambier JC. Fc gamma RIIB as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol 2001;108:S95-S98.
20. Bayary J, Dasgupta S, Misra N, et al. Intravenous immunoglobulin in autoimmune disorders: An insight into the immunoregulatory mechanisms. Int Immunopharmacol 2006;6:528-534.
21. Crow AR, Song S, Freedman J, et al. IVIg-mediated amelioration of ITP is not dependent upon key inflammatory regulators in a murine model [abstract]. Blood 2003;102:293a.
22. Cooper N, Meddle NM, Haas M, et al. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: Modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms. Br J Haematol 2004;124:511-518.
23. Sewell WA, North ME, Cambronero R, et al. In vivo modulation of cytokine synthesis by intravenous immunoglobulin. Clin Exp Immunol 1999;116:509-515.
24. Aukrust P, Froland SS, Liabakk NB, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994;84:2136-2143.
25. Berchtold P, Dale GL, Tani P, et al. Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood 1989;74:2414-2417.
26. Barbano G, Saleh MN, Mori PG, et al. Effect of intravenous gammaglobulin on circulating and platelet-bound antibody in immune thrombocytopenia. Blood 1989;73:662-665.
27. Lamoureux J, Aubin E, Lemieux R. Autoimmune complexes in human serum in presence of therapeutic amounts of intravenous immunoglobulins. Blood 2003;101:1660-1662.
28. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-493.
29. Kaveri S, Vassilev T, Hurez V, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996;97:865-869.
30. Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dinners: Studies in experimental immune thrombocytopenia. Blood 2001;98:1095-1099.
31. Ling ZD, Ziltener HJ, Webb BT, et al. Aggregated immunoglobulin and Fc fragment of IgG induce IL-6 release from human monocytes. Cell Immunol 1990;129:95-103.
32. Abe Y, Horiuchi A, Miyake M, et al. Anti-cytokine nature of natural human immunoglobulin: One possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994;139:5-19.
33. Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 1989;143:4104-4109.
34. Siragam V, Crow AR, Brinc D, et al. Intravenous immunoglobulin ameliorates ITP via activating Fc g receptors on dendritic cells. Nat Med 2006;12:688-692.